Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 3interventionalRules rewrite

Phase 3: testing Pirfenidone for Long COVID

The Long-Covid (LC)-Revitalize clinical study is testing repurposed drug treatments for Long Covid, involving adult participants from Brazil, Canada, Italy, South Africa, Uganda, the United States, and Zambia. To qualify, participants must have had Covid-19 and experienced Long Covid symptoms for at least three months.

Official registry: https://clinicaltrials.gov/study/NCT06928272 · Douglas D. Fraser · enrollment listed as 348

What this phase means

Phase 3: this treatment already looked useful in smaller studies. Now it is tested in a large group, often against standard care or a dummy treatment, to see if it should be approved.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Pirfenidone, Placebo for pirfenidone, or Upadacitinib. The registry lists allocation as randomized. The Long-Covid (LC)-Revitalize clinical study is testing repurposed drug treatments for Long Covid, involving adult participants from Brazil, Canada, Italy, South Africa, Uganda, the United States, and Zambia.

They plan to enroll about 348 people at 10 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

LC-REVITALIZE - A Long Covid Repurposed Drug Study

Interventions: Pirfenidone, Placebo for pirfenidone, Upadacitinib, Placebo for upadacitinib

Primary outcome (registry wording): Symptom Burden Questionnaire (SBQ) Subscales

Who it is for (from inclusion criteria)

  • Ages 18 Years to 65 Years
  • Eligible participants must meet all the following who can join:
  • Adults ≥ 18 years of age and ≤ 65 years of age
  • Previous Covid-19 (SARS-CoV-2 infection) within the past four years, as determined by the site investigator using the following certainty scale (based on available clinical history and/or serologic data):
  • 3 - Confirmed Infection (PCR or n-Capsid Test): Prior positive nasopharyngeal or salivary PCR test for Covid-19 (documented proof and/or verbal confirmation by participant) or has positive nucleocapsid antibodies results
  • 2 - Probable Infection (Antigen Test): Participant verbally confirms a prior positive rapid antigen test without PCR confirmation
  • 1 - Possible Infection (Viral Syndrome and Epidemiological Link): Participant verbally confirms experiencing symptoms consistent with Covid-19 infection and has an epidemiological link (i.e., exposure to a confirmed case) without any positive testing
  • 4\. At the time of screening, participants should be experiencing at least one of the following self-reported symptoms or symptom clusters. Participant has self-reported issues with:

Public study contact (from the registry)

Stephanie Perkin

1-519-685-8500

stephanie.perkin@lhsc.on.ca

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

10 listed

+ 9 sites outside the US on the same record

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phasePaiporta, Valencia
Not a traditional drug phase: Transcranial Direct Current Therapy (tDCS) for COVID-19

This study aims to verify the how well it works/effectiveness of treatment with transcranial direct current stimulation (TDCS) in patients with Long Covid who experience headaches, migraines, and chronic pain, such as arthralgia and myalgia, as well as sleep problems. Transcranial direct current stimulation is used in the field of Physiotherapy and Rehabilitation, with results that have proven to be effective for treating patients suffering from symptoms like migraines, headaches, chronic pain, fibromyalgia, or chronic neuropathic pain and insomnia.

NCT05780450 · Official ClinicalTrials.gov record · Fundación Universidad Católica de Valencia San Vicente Mártir

FAQ about this NCT record

Is NCT06928272 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT06928272?

Phase 3. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT06928272?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary